Come & Mingle

Since 2023, the FDA mandates have reshaped the dose optimization landscape in oncology, but new challenges emerge with oral dosing:

🚫 50% of Study Participants Deviate from Prescribed Dosing
⚠️ 40% of Exposure Data is Unreliable
💊 Drug Efficacy Underestimated, Safety Distorted

The stakes are high:

🔍 Poor Trial Results
⏳ Delays or Denial of Regulatory Approval
💸 Non or Partial Reimbursement for Off-Label Use

Join the WestRock, AARDEX Group to explore innovative solutions and strategies to tackle these critical issues. 

Let’s revolutionize drug exposure in clinical trials together!